ARCHIVE # 1: 1,457 HEADLINES from 8/2006 to 12/2004
Dr. Timothy L. Vollmer
Chairman, Division of Barrow Neurology

Director, Barrow NeuroImmunology Program

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
My Educational Video on MS and MS Trials
Produced by MD Health Channel
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT!
Visitors Since 03/2006!
Our 841 MySpace Friends
Join us..if you've been affected by MS
THIS COULD SAVE TOUR LIFE!
IF THERE IS A PROBLEM WITH ANY MS DRUG! READ THIS PLEASE: YOU NEED TO CLICK THE RED BUTTON BELOW & GET OUR FREE "MS News Alerts". WE SEND YOU BREAKING NEWS ON ALL MS DRUGS: Scroll down & read what we did last year...within 24 hours of the 1st death from the MS drug Tysabri!
IMPORTANT: We filmed the video below within hours of the 1st death from Tysabri and e-mailed it to everyone who clicked the Flashing Red Button above!...WATCH THE VIDEO...THEN CLICK THE FLASHING RED BUTTON ABOVE!
Timothy L. Vollmer M.D.
Director, Barrow NeuroImmunology Program
Barrow Neurological Institute
St. Joseph's Hospital and Medical Center


BARROW NEUROLOGICAL INSTITUTE'S GRAND CANYON
RIM-RIM-HIKE

Organized by Dr. Spetzler

250 Photo-Slideshow


Click to view 1280 MS Walk photos!

"Join a trial at Barrow & receive all medication & study based procedures at no charge!"
Stan Swartz, CEO, The MD Health Channel

"WE PRODUCED THE FOLLOWING 9 VIDEOS FOR YOU!"
Simply click the "video" buttons below:

.

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

"OUR TEAM IS WORKING ON A CURE FOR MS"
Runtime: 54 sec
Runtime: 54 sec
Susan N. Rhodes
Multiple Sclerosis Research
Barrow Neurological Institute

"'The 2006 Barrow Neurological Institute at St. Joseph's Hospital MS "Walk on the Wild Side" raised more than $460,000 with 3,500 walkers! Click on the blue link above to view photos"

Chris Uithoven
President
National Multiple Sclerosis Society
Arizona Chapter


"THE MS SOCIETY OFFERS MANY PROGRAMS TO HELP...EVERYTHING FROM PILATES & SUPPORT GROUPS TO HORSEBACK RIDING"
Jerry Turner
Program Director
National Multiple Sclerosis Society
Arizona Chapter

Previious Posts

MS NEWS ARCHIVES: by week
12.04  
01.05  
02.05  
03.05  
04.05  
05.05  
06.05  
07.05  
08.05  
09.05  
10.05  
11.05  
12.05  
01.06  
02.06  
03.06  
04.06  
05.06  
08.06  
09.06  
07.13  
04.14  

This page is powered by Blogger. Isn't yours?

September 08, 2005

 

Biogen Idec to cut 17 percent of work force, sell assets

Drug maker Biogen Idec Inc. on Thursday said it will lay off 650 workers, or about 17 percent of its work force, as part of a plan to reduce annual expenses by $200 million to $300 million.

The Cambridge-based biotechnology firm, seeking to regain its footing after withdrawing a multiple sclerosis drug over safety concerns, said it also plans to sell a San Diego manufacturing plant as well as the rights to Amevive, a psoriasis drug that generated $43 million in sales last year.

James C. Mullen, Biogen Idec's chief executive and president, said the company is "well-poised for near-term success'' but believes for the long term that it must cut programs "unlikely to create significant value.''

Biogen Idec announced the restructuring after its shares closed down 3 cents at $42.44 on the Nasdaq Stock Market, where the stock has traded in a 52-week range of $33.18 to $70.

Biogen Idec said the cuts to 650 positions worldwide will mostly occur by the end of the year, spread across various departments and locations. Of the total jobs to be cut, 250 will come from the company's Cambridge headquarters, which now has 1,700 employees.

Biogen Idec expects to take a pretax charge against its earnings of $30 million to $40 million to cover severance and restructuring costs resulting from the cuts.

The company has recently remained profitable despite its decision in February to withdraw the multiple sclerosis drug Tysabri. Biogen Idec developed the drug with its Irish partners, Elan Inc.,

The drug may heighten the risk of contracting a rare and often fatal disease of the central nervous system. The companies are completing a review of the drug's safety, and hope to report back to federal regulators by month's end in hopes that it will be found safe to return to the market, likely with a more restrictive warning label.

The drug was withdrawn after it was linked to two cases of a brain disease called progressive multifocal leukoencephalopathy, or PML. One of those patients died. On March 30, Elan and Biogen announced that a Crohn's sufferer who had been taking Tysabri also had died of PML

www.sanluisobispo.com